American Heart Journal
Volume 141, Issue 6 , Pages 893-898 , June 2001

The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design

Received 15 July 2000 ,Accepted 22 December 2000.

References 

  1. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844–2850
  2. Fuster V, Badimon L, Cohen M, et al.  Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213–1220
  3. Falk E. Why do plaques rupture?. Circulation. 1992;86:III-30–III-42
  4. van der Wal AC, Becker AE, van der Loos CM, et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44
  5. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al.  Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94:3090–3097
  6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  7. Ridker PM, Hennekens CH, Buring JE, et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  8. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  9. Farmer J. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000;2:208–217
  10. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991;23:118–124
  11. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52–58
  12. Tillet WS, Francis T. Serologic reactions in pneumonia with a nonprotein somatic fraction of pneumoccus. J Exp Med. 1930;52:561–571
  13. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136–2141
  14. Ridker PM, Buring JE, Shih J, et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733
  15. Ridker PM, Cushman M, Stampfer MJ, et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428
  16. Tracy RP, Lemaitre RN, Psaty BM, et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121–1127
  17. Kuller LH, Tracy RP, Shaten J, et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537–547
  18. Koenig W, Sund M, Frohlich M, et al.  C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242
  19. Danesh J, Whincup P, Walker M, et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204
  20. Mendall MA, Strachan DP, Butland BK, et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21:1584–1590
  21. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  22. Williams JK, Sukhova GK, Herrington DM, et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684–691
  23. Shiomi M, Ito T, Tsukada T, et al.  Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1938–1944
  24. Bustos C, Hernandez-Presa MA, Ortego M, et al.  HMG Co A reductase inhibition by atorvastatin reduces intimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057–2064
  25. Weber C, Erl W, Weber KS, et al.  HMG Co A reductase inhibitors decrease CD 11b expression and CD 11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212–1217
  26. Ridker PM, Rifai N, Pfeffer MA, et al.  Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–235
  27. Jialal I, Stein D, Balis D, et al.  Effect of HMG-CoA reductase inhibitor therapy on C-reactive protein levels. [abstract] Circ Suppl. 2000;108:4006
  28. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. [letter] Lancet. 1999;353:118–119
  29. Ridker PM, Rifai N, Miles JS, et al.  Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS. [abstract] Circ Suppl. 2000;108:4005

☆ Supported by a grant from Bristol-Myers Squibb Company, Plainsboro, NJ.

☆☆ Reprint requests: Michelle A. Albert, MD, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis St, Boston MA 02115. E-mail: maalbert@bics.bwh.harvard.edu

★ PRINCE is an investigator-initiated study from the Center of Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, Boston.

PII: S0002-8703(01)13493-9

doi: 10.1067/mhj.2001.115297

American Heart Journal
Volume 141, Issue 6 , Pages 893-898 , June 2001

Article Tools

* Image Usage & Resolution